BRCA mutation, ovarian ageing, anti-Mullerian hormone - Engels: AMH, BRCA, ovarian ageing - Nederlands: AMH, BRCA, ovariele veroudering.
Conditions
Interventions
26-jul-2014: The intervention has been a blood sample from the start of the trial. Due to misinterpretation, this was first interpreted as a therapeutical item.
Sponsors
UMC Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: - Female age between 18 and 45 years - Predictive genetic testing on BRCA mutation or a known BRCA carrier status - Regular menstrual cycles (i.e. mean cycle length of 21-35 days, with the next menstrual period predictable within a 7 days time frame) - Written informed consent
Exclusion criteria
Exclusion criteria: - Surgical menopause (i.e. premenopausal hysterectomy and/or bilateral ovariectomy) - Ovarian surgery - Chemo- or radiation therapy - Human immunodeficiency virus (HIV) infection - Known endocrine or autoimmune abnormalities (i.e. Cushing syndrome, type I Diabetes Mellitus, hypothyroidism, hyperprolactinemia, adrenal insufficiency, hypoparathyriodism, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus) - Known genetic abnormalities (structural or numerical abnormalities of the X-chromosome (i.e. Turner’s syndrome, fragile X syndrome), or abnormalities on human autosomal functionally relevant genes, others than a BRCA mutation, associated with primary ovarian insufficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| age specific AMH levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Reproductive health/ outcome | — |
Contacts
Public ContactF.J. Broekmans
Heidelberglaan 100
Outcome results
None listed